{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:01:11Z","timestamp":1788879671439,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1136\/ijgc-2018-000067","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T09:30:45Z","timestamp":1548235845000},"page":"341-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Robert D","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerissa","family":"Mescallado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjees","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2018-000067_bb0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"issue":"Suppl_4","key":"10.1136\/ijgc-2018-000067_bb0015","doi-asserted-by":"crossref","first-page":"iv259","DOI":"10.1093\/annonc\/mdy157","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ledermann","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2018-000067_bb0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2018-000067_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000067_bb0035","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0050","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1023\/A:1013558501425","article-title":"Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer","volume":"12","author":"Meyer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0055","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/IGC.0000000000001194","article-title":"An outpatient, dose-intense, intravenous cisplatin and oral etoposide regimen for the treatment of advanced, platinum-resistant ovarian cancer","volume":"28","author":"Morgan","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000067_bb0060","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6604914","article-title":"Extended weekly dose-dense paclitaxel\/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer","volume":"100","author":"Sharma","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2018-000067_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6600002","article-title":"Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer","volume":"86","author":"van der Burg","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2018-000067_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ijgc-00009577-200303000-00005","article-title":"Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study","volume":"13","author":"Bauknecht","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000067_bb0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-8258(03)00413-X","article-title":"Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study","volume":"91","author":"Belpomme","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0080","first-page":"3137","article-title":"A phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer","volume":"26","author":"Gallardo","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2018-000067_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00001813-200209000-00009","article-title":"Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer","volume":"13","author":"Nogu\u00e9","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1136\/ijgc-2018-000067_bb0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2003.09.021","article-title":"Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study","volume":"92","author":"Papadimitriou","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ygyno.2004.07.056","article-title":"Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma","volume":"95","author":"Villella","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ygyno.2006.09.006","article-title":"Biweekly gemcitabine and cisplatin in platinum-resistant\/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma","volume":"104","author":"Bozas","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/B:DRUG.0000036690.14585.a3","article-title":"Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma","volume":"22","author":"Tewari","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1136\/ijgc-2018-000067_bb0115","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0120","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0130","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1200\/JCO.1991.9.10.1801","article-title":"Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000067_bb0135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1054\/bjoc.2000.1643","article-title":"Estimation of glomerular filtration rate in cancer patients","volume":"84","author":"Wright","year":"2001","journal-title":"Br J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2018-000067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:37:03Z","timestamp":1753223823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24010776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1048891X24010776"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2018-000067","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2018-000067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}